San Diego-based clinical development platform Faro AI raised $37.3 million in Series B financing to scale its agentic artificial intelligence infrastructure across pharmaceutical workflows and clinical trials. Led by Chief Executive Officer Scott Chetham, Faro AI develops structured data models and AI agents designed to automate complex processes in clinical development. The fresh funding will support the deployment of specialized AI agents that assist biopharma researchers with trial design, protocol optimization, and regulatory workflows.
The platform creates structured data models that capture the underlying intent and relationships of clinical studies, allowing intelligent agents to perform reasoning across the development pipeline.
Key features of Faro’s AI platform include:
-
Streamlining clinical study design and protocol workflows
-
Reducing time from first-in-human trials to regulatory approval
-
Delivering structured data infrastructure adopted by leading global pharmaceutical companies
The Series B financing round was co-led by the Merck Global Health Innovation Fund and S32. The round saw full participation from existing investors, including General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, and Zetta, alongside new backer Ankona Capital.
The latest round brings Faro AI’s total disclosed funding to more than $75 million, reflecting growing industry demand for autonomous digital agents in drug discovery and clinical execution.
The digital health sector continues to witness significant investment activity across specialized healthcare automation platforms. Recent funding rounds include revenue assurance platform Arintra raising $25 million and behavioral health company Onos Health securing $17 million, demonstrating robust venture backing for healthcare artificial intelligence.
[FAQs] Frequently Asked Questions
1. What does Faro AI specialize in?
Faro AI provides structured data infrastructure and AI agents that help pharmaceutical and biotechnology companies automate clinical trial design, protocol planning, and regulatory workflows.
2. Who led Faro AI’s funding round?
The $37.3 million Series B financing was co-led by the Merck Global Health Innovation Fund and S32, with backing from General Catalyst, Polaris Partners, and Ankona Capital.
3. How will the capital be utilized?
Faro AI will use the funds to expand its agentic AI platform, accelerate clinical trial timelines, and support adoption across top global biopharmaceutical organizations.